Aptuit LLC and Dimension Therapeutics have entered strategic partnership agreement under which Aptuit will support GLP IND-enabling studies for select rare disease programs at Dimension. Aptiut has initiated three key development projects under the alliance.

Jonathan Goldman, chief executive officer, Aptuit LLC, said, “This partnership is designed to accelerate select late preclinical-stage programs at Dimension in a high-quality environment, supported by a culture of scientific excellence and innovation. This partnership builds upon Aptuit’s scientific excellence in integrated IND development in the exciting area of gene therapies.  In particular, we plan to ensure full and timeline resourcing of these programs, in order to increase probability of success, and reduce time and cost.”  

Dr. Annalisa Jenkins, MBBS, FRCP, chief executive officer of Dimension Therapeutics, said, “We are very pleased to announce the partnership with Aptuit. We share a common culture of scientific excellence and commitment to quality research and development. This alliance will allow select priority preclinical programs to progress effectively to IND, leveraging our joint expertise in the development of viral vector-mediated assets.”